MIRXES-B (02629) Reports Interim Results with Net Loss of US$28.35 Million Attributable to Shareholders, Narrowing 36.22% Year-on-Year
Stock News
Aug 25
MIRXES-B (02629) announced its interim results for 2025, reporting revenue of US$10.5 million, representing a 9.4% year-on-year increase. The company recorded a net loss attributable to equity shareholders of approximately US$28.35 million, which narrowed by 36.22% compared to the same period last year. The loss per share was US$0.185.
According to the announcement, the year-on-year revenue growth was primarily driven by increased revenue from GASTROClearTM and LUNGClearTM products within the early detection and precision multi-omics division, which offset a US$2.6 million revenue decline in the infectious diseases division resulting from the discontinuation of FortitudeTM product sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.